Pharmacogenetics testing for poor response to antidepressants: a transnosographic case series.

ABSTRACT:

Introduction

Pharmacogenetics (PGx) holds promise for optimizing psychotropic medication use, with CYP2D6 and CYP2C19 identified as key genes in antidepressant treatment. However, few studies have explored the genetic variants of these genes in real-world settings for patients experiencing ineffectiveness or adverse drug reactions (ADRs) to antidepressants.

Methods

This case series includes 40 patients who underwent PGx testing due to antidepressant ineffectiveness or ADRs between June 2020 and April 2022. We describe the patients' demographic, clinical, and genetic characteristics and assess the value of PGx testing based on feedback from their psychiatrists.

Results

The most common diagnoses were major depressive disorder (60.0%) and post-traumatic str

SUBMITTER: Lorvellec MA 

PROVIDER: S-EPMC11496244 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature